Newborn screening for SMA in Southern Belgium.
Newborn screening
SMN1
Spinal muscular atrophy
Werdnig-Hoffmann disease
qPCR
Journal
Neuromuscular disorders : NMD
ISSN: 1873-2364
Titre abrégé: Neuromuscul Disord
Pays: England
ID NLM: 9111470
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
24
05
2018
revised:
07
02
2019
accepted:
11
02
2019
pubmed:
30
4
2019
medline:
13
5
2020
entrez:
30
4
2019
Statut:
ppublish
Résumé
Approval was recently granted for a new treatment for spinal muscular atrophy (SMA). Given that the treatment is effective when administered early and the societal burden of SMA-related disability, the implementation of a newborn screening program is warranted. We describe the stepwise process that led us to launch a newborn screening program for SMA in Southern Belgium. Different political, ethical, and clinical partners were informed about this project and were involved in its governance, as were genetic and screening labs. We developed and validated a newborn screening method to specifically recognize homozygous deletions of exon 7 in the SMN1 gene. Subsequently, a 3-year pilot study has been recently initiated in one Belgian neonatal screening laboratory to cover 17.000 neonates per year. Coverage extension to all of Southern Belgium to screen 55.000 babies each year is underway.
Identifiants
pubmed: 31030938
pii: S0960-8966(18)30482-6
doi: 10.1016/j.nmd.2019.02.003
pii:
doi:
Substances chimiques
Oligonucleotides
0
SMN1 protein, human
0
Survival of Motor Neuron 1 Protein
0
nusinersen
5Z9SP3X666
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
343-349Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.